1. Home
  2. NAMSW vs LPLA Comparison

NAMSW vs LPLA Comparison

Compare NAMSW & LPLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • LPLA
  • Stock Information
  • Founded
  • NAMSW N/A
  • LPLA 1989
  • Country
  • NAMSW Netherlands
  • LPLA United States
  • Employees
  • NAMSW 29
  • LPLA N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • LPLA Investment Bankers/Brokers/Service
  • Sector
  • NAMSW Health Care
  • LPLA Finance
  • Exchange
  • NAMSW Nasdaq
  • LPLA Nasdaq
  • Market Cap
  • NAMSW N/A
  • LPLA N/A
  • IPO Year
  • NAMSW N/A
  • LPLA 2010
  • Fundamental
  • Price
  • NAMSW $10.10
  • LPLA $263.66
  • Analyst Decision
  • NAMSW
  • LPLA Buy
  • Analyst Count
  • NAMSW 0
  • LPLA 12
  • Target Price
  • NAMSW N/A
  • LPLA $287.27
  • AVG Volume (30 Days)
  • NAMSW N/A
  • LPLA 507.1K
  • Earning Date
  • NAMSW N/A
  • LPLA 07-25-2024
  • Dividend Yield
  • NAMSW N/A
  • LPLA 0.46%
  • EPS Growth
  • NAMSW N/A
  • LPLA 2.00
  • EPS
  • NAMSW N/A
  • LPLA 13.26
  • Revenue
  • NAMSW N/A
  • LPLA $10,467,609,000.00
  • Revenue This Year
  • NAMSW N/A
  • LPLA $18.97
  • Revenue Next Year
  • NAMSW N/A
  • LPLA $15.62
  • P/E Ratio
  • NAMSW N/A
  • LPLA $19.88
  • Revenue Growth
  • NAMSW N/A
  • LPLA 16.92
  • 52 Week Low
  • NAMSW N/A
  • LPLA $200.18
  • 52 Week High
  • NAMSW N/A
  • LPLA $289.88
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 57.49
  • LPLA 32.41
  • Support Level
  • NAMSW $9.40
  • LPLA $262.64
  • Resistance Level
  • NAMSW $10.14
  • LPLA $284.59
  • Average True Range (ATR)
  • NAMSW 0.68
  • LPLA 5.07
  • MACD
  • NAMSW 0.14
  • LPLA -1.91
  • Stochastic Oscillator
  • NAMSW 71.43
  • LPLA 4.65

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: